Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%. The response was similar regardless of PD-L1 status, and response was related to tumor mutational burden.
0
0 comments